FDA concludes examination of Parkinson's drug

The Food and Drug Administration announced Thursday it had not identified any "new or unexpected safety find...

Posted: Sep 21, 2018 11:50 AM
Updated: Sep 21, 2018 11:50 AM

The Food and Drug Administration announced Thursday it had not identified any "new or unexpected safety findings" related to a drug used to treat psychosis in Parkinson's patients, though it did find potentially troubling prescribing practices.

Nuplazid, which hit the market in 2016, is the only medication approved to treat hallucinations and delusions associated with a debilitating condition known as Parkinson's disease psychosis. It has been cited as a "suspect" medication in hundreds of deaths voluntarily reported to the agency, as highlighted in a CNN report earlier this year.

Business and industry sectors

Business, economy and trade

Diseases and disorders

Government organizations - US

Health and medical

Neurological disorders and injuries

Parkinson's disease

Pharmaceutical industry

Pharmaceuticals and biotechnology

Pharmaceuticals and prescription drugs

US Department of Health and Human Services

US federal departments and agencies

US Food and Drug Administration

Medical experts told CNN at the time that the high number of so-called "adverse event reports" deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.

Nuplazid's initial review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.

After CNN published its investigation on Nuplazid, reporters were contacted by family members who said they believed the drug contributed to their loved one's decline or death. Others said Nuplazid helped tame hallucinations with few apparent side effects.

The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.

On Thursday, the FDA said it had completed a review of these deaths and other adverse events that had been reported to the agency.

"Overall, the postmarketing data were consistent with the safety data obtained from the premarketing controlled clinical trials of Nuplazid for Parkinson's disease psychosis," it stated.

Acadia Pharmaceuticals, the company that manufactures Nuplazid, welcomed the FDA findings. "Nothing is more important to Acadia than the wellbeing of the patients who use Nuplazid," Steve Davis, the company's president and chief executive officer, said in a statement. "We are very pleased with the FDA's clear statement reaffirming Nuplazid's positive benefit-risk profile."

Dr. Paul Andreason, the physician who led the FDA's initial medical review of Nuplazid, had warned at the time of Nuplazid's approval that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.

In its statement this week, the FDA noted that like other antipsychotics, the drug already has the agency's most severe "black box" warning about the increased risk of death for the treatment of elderly dementia patients.

The agency also said its review had found "potentially concerning prescribing patterns," such as the use of Nuplazid with other antipsychotic drugs or with medications that can cause heart issues. It urged health care providers to familiarize themselves with the warnings and precautions associated with Nuplazid when prescribing it to patients.

The FDA said it would continue to monitor reports of adverse events and encouraged patients and doctors to report any suspected side effects to the agency.

Do you have information to share about Nuplazid or other drugs targeting the elderly? Email us: watchdog@cnn.com.

This story has been updated with a statement from Acadia Pharmaceuticals.

West Lafayette
Clear
81° wxIcon
Hi: 80° Lo: 53°
Feels Like: 81°
Kokomo
Clear
78° wxIcon
Hi: 78° Lo: 51°
Feels Like: 79°
Rensselaer
Clear
75° wxIcon
Hi: 79° Lo: 50°
Feels Like: 75°
Fowler
Clear
75° wxIcon
Hi: 78° Lo: 52°
Feels Like: 75°
Williamsport
76° wxIcon
Hi: 77° Lo: 52°
Feels Like: 78°
Crawfordsville
Clear
74° wxIcon
Hi: 78° Lo: 53°
Feels Like: 74°
Frankfort
Broken Clouds
78° wxIcon
Hi: 79° Lo: 51°
Feels Like: 79°
Delphi
Clear
76° wxIcon
Hi: 80° Lo: 51°
Feels Like: 76°
Monticello
Clear
76° wxIcon
Hi: 81° Lo: 51°
Feels Like: 76°
Logansport
Clear
75° wxIcon
Hi: 78° Lo: 50°
Feels Like: 75°
Very Warm, Then Rainfall Potential, Followed by Much Cooler Weather
WLFI Radar
WLFI Temps
WLFI Planner

Indiana Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 113337

Reported Deaths: 3530
CountyConfirmedDeaths
Marion20936761
Lake10334319
Elkhart6438109
St. Joseph6226103
Allen6060200
Hamilton4761109
Vanderburgh349430
Hendricks2681122
Monroe251236
Tippecanoe231213
Johnson2279123
Clark215756
Porter209046
Cass19339
Delaware189561
Vigo178524
Madison161075
LaPorte138239
Floyd132161
Howard129063
Warrick122336
Kosciusko120617
Bartholomew115357
Marshall99424
Dubois95918
Boone95646
Hancock91443
Grant89733
Noble89432
Henry78125
Wayne74714
Jackson7429
Morgan70638
Shelby66629
Daviess65428
Dearborn63928
LaGrange63211
Clinton59513
Harrison56424
Putnam53810
Lawrence50628
Montgomery50521
Knox5039
Gibson4894
White48214
DeKalb46311
Decatur45739
Miami4303
Greene41935
Fayette41813
Jasper3862
Steuben3747
Scott35910
Sullivan33112
Jennings31212
Posey3090
Franklin30325
Clay2985
Orange28624
Ripley2828
Carroll27113
Wabash2628
Washington2611
Whitley2556
Starke2537
Adams2523
Wells2503
Jefferson2443
Fulton2352
Huntington2223
Spencer2223
Tipton22022
Perry21513
Randolph2097
Jay1750
Newton17211
Owen1671
Martin1640
Rush1534
Pike1411
Vermillion1260
Fountain1202
Pulaski1151
Blackford1133
Brown1033
Crawford1030
Parke961
Benton880
Ohio777
Union770
Switzerland690
Warren391
Unassigned0225

COVID-19 Important links and resources

As the spread of COVID-19, or as it's more commonly known as the coronavirus continues, this page will serve as your one-stop for the resources you need to stay informed and to keep you and your family safe. CLICK HERE

Closings related to the prevention of the COVID-19 can be found on our Closings page.

Community Events